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Summary 
In cells infected with herpes simplex virus type 1, intracellular dNTP pools 
increased markedly. Treatment of these cells with 3 PM acyclovir resulted in an 
additional expansion in pyrimidine deoxyribonucleoside triphosphate pools 
with dTTP increasing 32-fold and dCTP g-fold. Both thymidine and 
deoxycytidine, however, compete with acyclovir for phosphorylation by the 
viral pyrimidine deoxyribonucleoside kinase and thus reduce the amount of 
drug that is anabolized to the active form. Theoretically, agents which inhibit 
thymidylate synthase or dihydrofolate reductase should reduce intracellular 
pools of thymidine, resulting in the potentiation of the antiviral effects of 
acyclovir. We explored this strategy by quantitating the synergy produced by 
combinations of acyclovir and other drugs using three-dimensional dose- 
response surface methodology (MacSynergy @ II). Significant synergy was seen 
with both 5FdUrd and methotrexate whereas BrVdUrd, 5-CldUrd, 5-IdUrd, 
and 5-BrdUrd exhibited little to no synergistic activity. It is suggested that 
inhibitors of thymidylate synthase and dihydrofolate reductase warrant further 
exploration as potentiators of acyclovir. 
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Introduction 
Of the drugs currently available for use in the United States, acyclovir (ACV, 
acycloguanosine, Zovirax”‘) is now established as an effective and well- 
tolerated therapeutic agent for the management of many herpes simplex virus 
(HSV) and varicella-zoster virus (VZV) infections in both immunocompetent 
and immunocompromised patients (Reardon and Spector, 1991). The 
biochemical basis for the high degree of selectivity of ACV is a result of 
differences that exist between herpesvirus-encoded and cellular enzymes. ACV 
is selectively phosphorylated by the HSV-encoded pyrimidine deoxyribonucleo- 
side kinase (TK) to the level of the monophosphate (Jamieson et al., 1974; 
Elion et al., 1977). Cellular kinases further phosphorylate ACV monophos- 
phate to the level of the triphosphate (ACVTP) which is the active form of the 
drug (Miller and Miller, 1980). Incorporation of ACVTP by the HSV DNA 
polymerase results in the apparent inactivation of this enzyme (Reardon and 
Spector, 1989). The sequential selectivity of phosphorylation and incorporation 
result in specific inhibition of viral DNA synthesis. 
The ability of ACV to inhibit virus replication, however, is dependent on its 
ability to compete with pyrimidine deoxyribonucleosides for initial phosphor- 
ylation by the viral TK (Harmenburg, 1983). Both infection with HSV-I and 
treatment with ACV dramatically increase intracellular pyrimidine deoxy- 
ribonucleoside pools and consequently limit the efficacy of ACV (Cheng et al., 
1975; Cheng and Ostrander, 1976; Furman, 1982; Harmenburg, 1983; Karlsson 
et al., 1988). To counteract this effect, intracellular pyrimidine deoxyribonu- 
cleoside pools could be suppressed to increase the activation of ACV. 
Theoretically, any compound which reduces intracellular pyrimidine deoxy- 
ribonucleoside pools could potentiate the antiviral effect of ACV. 
To test this hypothesis, we evaluated combinations of ACV and agents which 
depress intracellular pyrimidine deoxyribonucleoside pools. Since inhibitors of 
thymidylate synthase (TS) and dihydrofolate reductase (DHFR) deplete 
deoxypyrimidine pools, we chose inhibitors of these enzymes as candidate 
agents. Some members of the 5halogenated deoxyuridine series inhibit TS and 
have been shown to reduce intracellular thymidine pools at nontoxic 
concentrations (Heidelberger, 1975). Additionally, E-5-(2-bromovinyl)-1-2’- 
deoxyuridine (BrVdUrd), an inhibitor of TS, was evaluated in combination 
with ACV. In a manner analogous to ACV, BrVdUrd is selectively 
phosphorylated to the 5’-monophosphate by the virus-encoded TK (Balzarini 
et al., 1987). Methotrexate (MTX), a folate analog known to reduce 
intracellular pools of thymidine through the inhibition of DHFR (Hryniuk, 
1975) was also evaluated in combination with ACV. 
The experiments presented in this communication reveal that as predicted, 
inhibitors of both thymidylate synthase and dihydrofolate reductase potentiate 
the antiviral effect of ACV. 
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Materials and Methods 
Chemicals 
ACV was provided through the courtesy of Dr. Sandra Lehrman of the 
Burroughs Wellcome Company, Research Triangle Park, NC. MTX, 5- 
fluorodeoxyuridine (5-FdUrd), 5-chlorodeoxyuridine (5-CldUrd), 5-bromo- 
deoxyuridine (5-BrdUrd), and 5-iododeoxyuridine (5-IdUrd) were obtained 
from Sigma Chemical Company (St Louis, MO). HPLC-grade KH2P04 was 
obtained from ICN Biomedical, Costa Mesa, CA. 
Cell lines and viruses 
BS-C-l cells, an established line of African green monkey kidney cells, were 
grown in monolayers in minimal essential medium with Earle salts [MEM(E)] 
supplemented with 10% calf serum as described previously (Prichard et al., 
1990). Cells were routinely passaged with 0.05% trypsin plus 0.02% EDTA in 
HEPES-buffered saline (HBS) (Shipman, 1969). The KOS strain of HSV-1 was 
obtained from Dr. Sandra Weller at the University of Connecticut, 
Farmington, CT. The virus was grown and titered as described previously 
(Prichard et al., 1990). 
Deoxyrihonucleoside triphosphate pool determinations 
Triplicate 162 cm2 flasks (CostarH’, Cambridge, MA) containing exponen- 
tially growing BS-C-l cells were passed 12 h prior to infection and/or drug 
treatment. Approx. 3-6 x lo6 exponentially growing BS-C-l cells were infected 
with the KOS strain of HSV-1 at a multiplicity of infection of 10. Drugs were 
added, following a 1 h adsorption period. 6 h post-infection, the cells were 
washed twice with HBS at 37°C and trypsinized as described above. The 
extraction protocol is based on the procedure described previously (Garret and 
Santi, 1979). Briefly, the cells were pelleted and 75 ~1 of ice cold 0.6 M 
trichloroacetic acid (TCA) and an internal standard of [ H]dThd was added to 
the cell pellet. The cells were extracted for a minimum of 15 min on ice and the 
solution was filtered through a 0.22 PM SPIN-X centrifuge filter unit (Costar I”, 
Cambridge, MA) at 4°C. The TCA was extracted from the solution by adding 
125 ~1 of freon with 0.5 M trioctylamine to the filtrate and vortexing. The 
upper aqueous phase containing the deoxyribonucleoside triphosphates was 
aliquoted and frozen at -77°C. 
Ribonucleotides were cleaved via a periodate oxidation reaction (personal 
communication by Dr. Donald Nelson, Burroughs Wellcome Company, 
Research Triangle Park, NC). Briefly, to each sample 8 ~1 of 0.25 M sodium 
metaperiodate (Fisher Scientific, Fair Lawn, NJ) was added and vortexed. 
Following a 4 min incubation period at 20°C 10 ~1 of 4 M methylamine 
phosphate (pH 7.5) was added, vortexed and incubated for 30 min at 37°C. The 
reaction was stopped by adding 10 ~1 of both 1 M HCl and 1 M glucose and the 
samples were frozen at -77°C until separation by HPLC. The dNTPs were 
separated with a Spectraphysics HPLC (Spectraphysics, San Jose, CA) on a 4.6 
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mm x 25 cm ultrasil AX column with a 3.2 mm x 4.5 cm ultrasil AX 
precolumn (Beckman Instruments, Fullerton, CA). The column was equili- 
brated with 0.3 M KH2P04 at pH 3.75 and samples were separated with a 5 
min isocratic elution at 2 ml/min with 0.3 M KHzP04 at pH 3.75 followed by a 
25 min linear gradient from 0.3 M to 0.75 M at pH 3.75. 
Antiviral enzyme immunoassay 
The antiviral enzyme immunoassay utilized is similar to the one described 
previously (Prichard and Shipman, 1990). Briefly, an EIA was performed in 
situ in wells of 96 well plates containing the infected cell sheets. The wells were 
first blocked with 200 ,~l HBS with 0.05% Tween-20 (HBS-T) with 10% horse 
serum for 1 h at 37°C. The plates were then shaken out and 50 ,ul of a 1:400 
dilution of horseradish peroxidase (HRP) conjugated rabbit anti-HSV- 1 
antibodies (Dako, Santa Barbara, CA) in HBS-T supplemented with 10% 
horse serum, were then added to each well. Following a 1 h incubation at room 
temperature, the plates were washed 4 times with HBS-T. The plates were 
subsequently developed with 150 ~1 of a substrate solution consisting of 35 mM 
citric acid, 67 mM Na2HP04 at pH 5.0, 0.005% (v/v) 30% H202 and 1 mg/ml 
tetramethyl benzidine (TMB; Sigma Chemical, St. Louis, MO). The reaction 
was stopped with 50 ,ul of 2 M H2S04 and read at 450/570 nm in a microplate 
bio-kinetics reader (Biotek Instruments, Winooski, VT). 
Synergy analysis 
To characterize the drug-drug interactions, a three-dimensional analytical 
method was performed with shareware developed in our laboratory 
(MacSynergy@ II). Earlier versions of this analytical method have been 
described elsewhere (Prichard and Shipman, 1990; 1992). Briefly, theoretical 
additive interactions were calculated from the dose-response curves of the 
individual drugs. This calculated additive surface, which represents the 
predicted additive interactions, was then subtracted from the experimental 
surface to reveal regions of greater than expected interaction (synergy). The 
resulting surface would appear as a horizontal plane at 0% inhibition above 
calculated if the interactions were merely additive. Any peaks above this plane 
would be indicative of synergy. Similarly, any depression below the plane 
would indicate antagonism. 
The 95% confidence intervals about the experimental dose-response surface 
were used to evaluate the data statistically. For each point in the plot, if the 
lower 95% confidence limit of the experimental data was greater than the 
calculated additive surface, the synergy was considered to be significant. 
Conversely, if the upper 95% confidence limit of the experimental data was less 
than the calculated additive surface the antagonism was considered to be 




Effects of HSV-I infection and acyclovir treatment on intracellular dNTP pools 
Drugs dCTP dTTP 




(Pmol/ I Oh cells) 
Uninfected 69 * I3 17 * 9 69 f 3 25 f 5 
HSV-I KOS 420 f 55 2180 * 354 146 f I2 167 f 31 
HSV-I KOS 554 f 59 2480 k 269 261 f 37 212 * 51 
3 FM ACV 
Cytotoxicity determinations 
Simultaneous cytotoxicity assays were done as above except that the plates 
were not infected with virus. Cell growth was quantitated as described 
previously (Prichard et al., 1991). Briefly, growth of KB cells (an established 
human cell line derived from an epidermoid carcinoma of the mouth) was 
quantitated by staining the cell sheet with crystal violet and measuring the 
bound dye by eluting with 1% (v/v) HCl in ethanol. The optical density was 
determined at 570/405 nm in a microplate bio-kinetics reader (Biotek, 
Winooski, VT). Data were analyzed as described above. 
Results 
Deoxyribonucleoside triphosphate pools 
HSV- 1 infection significantly increased each of the intracellular dNTP pools 
with dTTP increasing 2%fold and dCTP increasing 6-fold (Table 1). When 
infected cells were treated with 3 ,uM ACV, dTTP pools increased by 32-fold 
and dCTP pools by &fold compared with values for uninfected untreated cells. 
These increases in intracellular pyrimidine dNTPs are consistent with 
observations published by others (Furman, 1982; Harmenburg, 1983; 
Karlsson et al., 1988). 
TABLE 2 
Antiviral activity (I&,), cytotoxicity (TCSo) and potentiation of the antiviral effect of acyclovir by a 
series of inhibitors of thymidylate synthase and dihydrofolate reductase 
Data are presented as the arithmetic mean of two experiments (except as noted) 
Compound name TC(50) (FM) IC(50) (PM) Synergy with ACV (PM*%) 
ACV > 100 0.5 
5-FdUrd 0.25 0.02 80” 
5-CldUrd 65 0.59 4 
5-BrdUrd > 100 0.89 0 
5-IdUrd 70 2.0 3 
BrVdUrd > 100 I.2 8 
MTX 28 0.1 I 47” 
“Average of three separate experiments. 
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Antiviral activity and cytotoxicity 
Each of the compounds was evaluated individually in terms of both antiviral 
effect (I(&) and cytotoxicity (T&J. The antiviral activity and cytotoxicity of 
these compounds are shown in Table 2. 
Synergy with ACV and 5-halogenated deoxyuridines 
In the Shalogenated deoxyuridine series, 5-FdUrd clearly was the best 
potentiator of ACV in terms of antiviral activity (Table 2). The average volume 
of synergy produced by this combination was 80 FM*% at a level of confidence 
of 95%. The results from a typical experiment are shown in Fig. 1. In this 
experiment, the synergy had a volume of 34 FM*% at 95% confidence (Fig. 
1A) and the optimal drug concentrations were 0.37 PM ACV and 0.014 FM 5- 
FdUrd (Fig. 1 B). This appeared to be a specific antiviral effect as no significant 













Fig. I. Synergistic antiviral interactions with combinations of acyclovir and Sfluorodeoxyuridine (5- 
FdUrd). The synergy plot in both three-dimensional (A) and contour form (B) reveals the antiviral synergy 
produced by ACV and 5-FdUrd at the 95% level of confidence. In the representative experiment shown 
here, the volume of synergy produced by this combination had a volume of 34 /iM’% at 95% conlidence. 
Maximal synergy was observed at 0.37 /IM ACV and 0.014 FM 5-FdUrd. 
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in this series produced little or no significant synergy and we consider the 
interactions to be negligible (Table 2). Interestingly, in this series of compounds 
only 5-FdUrd is an inhibitor of TS (De Clercq et al., 1978). 
Synergy with AC V und Br VdUrd 
Combinations of BrVdUrd and ACV showed very little significant 
synergistic antiviral activity (8 pM2% at 95% confidence). This synergy was 
not significant at 99% confidence and we consider these interactions to be 
negligible. BrVdUrd has been shown to inhibit TS in infected cells, but was 
unable to potentiate the antiviral effects of ACV. However, unlike the 5- 
halogenated deoxyuridines, BrVdUrd is phosphorylated exclusively by the viral 
TK and competes with ACV for phosphorylation (Balzarini et al., 1987). This 
competition may overcome the possible benefit of reducing deoxypyrimidine 
pools in infected cells. 
Synergy with ACV and MTX 
Pyrimidine deoxyribonucleoside pools can also be suppressed with folic acid 
analogs. Significant synergistic antiviral interactions were seen with the 
combination of MTX and ACV and had an average volume of 47 pM2% at 
95% confidence (Table 2). The results from a typical experiment are shown in 
Fig. 2. In this experiment, the volume of synergy produced was 40 PM’% at 
95% confidence (Fig. 2A). The optimal drug concentrations were 0.37 ,LLM 
ACV and 0.123 PM MTX (Fig. 2B). Again this appeared to be a specific 
antiviral effect as no synergistic cytotoxicity was observed (data not shown). 
Discussion 
Previous reports have demonstrated that high levels of thymidine reduce the 
efficacy of ACV by competing for phosphorylation by the HSV TK 
(Harmenberg, 1983). In the present report, we demonstrate that agents which 
suppress intracellular pyrimidine deoxyribonucleoside pools by inhibiting 
thymidylate synthase or dihydrofolate reductase significantly increase the 
efficacy of ACV. 
We examined the ability of a series of compounds to potentiate the antiviral 
effects of ACV. In the 5-halogenated deoxyuridine series, only 5-FdUrd was 
able to potentiate the antiviral effect of ACV. In this series only 5-FdUrd is a 
potent inhibitor of TS and results in decreased pyrimidine deoxyribonucleoside 
pools (De Clercq et al., 1978; Descamps et al., 1982). The structure-synergy 
relationship observed here correlates well with the TS inhibition produced by 
halogenated deoxyuridines and supports the hypothesized mechanism of 
synergy. MTX reduces intracellular pyrimidine deoxyribonucleoside pools 
through a different mechanism (inhibition of DHFR) (Hryniuk, 1975). As 
predicted, this drug also efficiently potentiated the antiviral effects of ACV. As 
with 5-FdUrd, the synergy is most likely mediated by the depression of 
256 
Fig. 2. Synergis, . dntlv, I interactions with combinations of acyclovir and the folate analog methotrexatc 
(MTX). The synergy plot m both three-dimensional (A) and contour form (B) reveals the antiviral synergy 
produced by ACV and MTX at the 95% level of confidence. In the representative experiment shown here, 
the volume of synergy produced by this combination was 40 PM’% at 95% confidence. Maximal synergy 
was observed at 0.37 PM ACV and 0.123 /IM MTX. 
pyrimidine deoxyribonucleoside pools and a corresponding increase in the level 
of ACV phosphorylation. 
We conclude that the antiviral effect of ACV can be potentiated by drugs 
that are capable of inhibiting either thymidylate synthase or dihydrofolate 
reductase. In the case of TS, an earlier observation by Cheng and coworkers 
(1983) demonstrated that 5-FdUrd and ACV appeared to interact synergisti- 
cally at the single concentrations studied. Structure-synergy relationships in the 
halogenated deoxyuridine series correlated well with TS inhibition by the 
individual agents. The single exception to this rule was BrVdUrd. BrVdUrd is 
known to inhibit TS in HSV-infected cells and yet did not potentiate the 
antiviral effect of ACV. Unlike the 5-halogenated deoxyuridines, BrVdUrd is 
phosphorylated exclusively to the active form (BrVdUrd monophosphate) by 
the HSV TK. Consequently, BrVdUrd competes with ACV for activation by 
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the HSV TK and probably results in reduced phosphorylation of either ACV, 
BrVdUrd, or both drugs. This competition may overcome the possible benelit 
of reducing pyrimidine deoxyribonucleoside pools in infected cells. 
Several reports have shown that the suppression of intracellular deoxyguan- 
osine triphosphate (dGTP) pools by inhibitors of the HSV ribonucleotide 
reductase potentiate the antiviral effects of ACV (Spector et al., 1985; 1987; 
1989; 1991). In this report, we show that it is also possible to potentiate the 
antiviral effects of ACV through TS or DHFR inhibition. This strategy was 
effective in inhibiting the replication of herpes simplex virus and should be even 
more effective against varicella-zoster virus which encodes a distinct TS. 
Reducing intracellular dGTP pools results in the potentiation of ACV 
(Spector et al., 1985; 1987; 1989; 1991). It is also possible to potentiate ACV 
with inhibitors of TS or DHFR, presumably by reducing intracellular 
pyrimidine deoxyribonucleoside pools. These two mechanisms of ACV 
potentiation are not mutually exclusive and both of these strategies could be 
used simultaneously to optimize the efficacy and selectivity of ACV. In fact, a 
three-drug combination that utilizes both of these mechanisms has been shown 
to be a very potent inhibitor of viral replication (Prichard et al., submitted). 
The potentiation produced by this strategy was shown to be superior to the 
potentiation produced by either inhibitors of the HSV ribonucleotide reductase 
or by inhibitors of TS. 
The structure-synergy relationships established here suggest that the 
reduction of intracellular pyrimidine deoxyribonucleoside pools could 
potentiate the antiviral effects of ACV. These experiments identified the most 
potent drug combination against HSV and identified optimal drug concentra- 
tions. We propose that inhibitors of thymidylate synthase and dihydrofolate 
reductase warrant further exploration as potentiators of acyclovir. 
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